Mean Difference: 7.6
Patient-reported outcome measures in pulmonary hypertension, such as the emPHasis-10 score, must be linked to predefined clinical response pathways to meaningfully alleviate symptom and treatment burden.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Nascimento et al. (2026) conducted a letter in Pulmonary hypertension. Prostacyclin pathway therapies was evaluated on emPHasis-10 score (7.6-point increase).
Synapse has enriched 5 related papers. Consider them for comparative context: